ULTRAPROACTIVE THERAPEUTIC DRUG MONITORING BASED ON POINT-OF-CARE TESTING OF INFLIXIMAB IS NOT SUPERIOR TO REACTIVE DRUG MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: 1 YEAR RESULTS OF A PRAGMATIC CLINICAL TRIAL

Peter Bossuyt  ¹     Sophie Claeys  ²     Soetkin D'haens  ²     Eveline Hoefkens  ²     Beatrijs Strubbe  ²     Denis Marichal  ²     Lieven Pouillon  ²     Harald Peeters  ^2    
1 Imelda GI Clinical Research Center, Bonheiden, Belgium
² St-Lucas IBD Clinic, Gent, Belgium

Topic
Gut Microbiota, IBD, Immunology

Session
IBD: Drug monitoring

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)